An official website of the United States government
Home
Name
VAL-083
Alternate Names
None
Abbreviations
None
Category
Other therapy
Subcategory
None
NSC Number
None
Primary Site
Brain
Histology
Glioma, glioblastoma
Remarks
January 15, 2016: VAL-083 is currently in phase II clinical studies at MD Anderson for treatment of first recurrence/progression of GBM.
April 2016: The FDA granted Orphan Drug Designation to VAL-083 in the treatment of ovarian cancer.
CODE: code as Other Treatment, assign code 2
April 2016: The FDA granted Orphan Drug Designation to VAL-083 in the treatment of ovarian cancer.
CODE: code as Other Treatment, assign code 2
Coding
Please see remarks for additional information
